mRNA Vaccines for Cancer Treatment
The success of mRNA COVID-19 vaccines has helped accelerate clinical research on mRNA vaccines to treat cancer. mRNA Vaccine technology is extremely promising for infectious diseases and can lead to development of vaccines in the treatment of cancer. Dozens of clinical trials are testing mRNA treatment vaccines in people with various types of cancer, including pancreatic cancer, colorectal cancer, and melanoma. Some vaccines are being evaluated in combination with drugs that enhance the body’s immune response to tumors. However, mRNA cancer vaccines have yet to be approved by the US Food and Drug Administration for use either alone or with other cancer treatments.
Protein Synthesis
Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of cancer immunotherapy. With the ease of rapid, large-scale Good Manufacturing Practice-grade mRNA production, mRNA is ideally poised not only for off-the shelf cancer vaccines but also for personalized vaccination for your neoantigens.
Immune Response
With this approach, researchers try to elicit an immune response against abnormal proteins, your neoantigens, produced by cancer cells. Because these proteins are not found on normal cells, they are promising targets for vaccine-induced immune responses. Personalized cancer vaccines can stimulate the immune system to recognize cancer cells from healthy cells, and kill only the cancer.
About Personalized Precision (n=1) mRNA Cancer Vaccines
Targeted
Normax investigational mRNA cancer vaccines will be manufactured for individuals based on the specific molecular features of their tumors which are called neoantigens. Training your immune system to recognize these neoantigen protein targets on the surface of your cancer cells could empower your body to control your cancer.
Personalized
For more than a decade, cancer researchers have been developing a type of treatment known as a personalized cancer vaccine using various technologies, including mRNA and protein fragments, or peptides to target your neoantigens of your cancer. A personalized mRNA vaccine from Normax could be a safe and effective tool for your doctors to use in the arsenal to fight your cancer.
Rapid Delivery
Normax plans to produce a personalized mRNA cancer vaccine for you, after tissue samples have been collected, within 1 to 2 months. Speed is especially important for individualized cancer vaccination. Ideally, a highly individualized vaccine combination to target your neoantigens should be designed and produced within 10 weeks of taking your tumor biopsy and blood sample.
mRNA Cancer Vaccine Production
Step 1
Identifying the unique mutations of your cancer by comparing the differences of the DNA sequences of your cancer cells and your normal cells.
Step 2
Selecting and testing the patient cancer mutations that could his natural immune system to launch the most effective attack on the cancer cells.
Step 3
Using mRNA vaccine technology to produce the personalized cancer vaccine mRNA
”Normax strategic locations in Belgium, United Kingdom, and California are enabling Normax to leverage the expertise of leading oncologists, researchers and clinicians, further accelerating the development and delivery of personalized mRNA cancer vaccines for cancer patients. Together, we can make a real difference in the fight against cancer with personalized immunotherapy.”
Cancer Vaccine Technology
Clinical Trials
Normax is initiating clinical trial testing of personalized mRNA vaccines to target individual neoantigens. The goal is a complete and enduring response whereby all signs of the tumor disappear following treatment.
Advanced AI Analytics
The manufacturing process starts with the identification of genetic mutations in a patient’s tumor cells that could give rise to neoantigens. Advanced AI Analytics then predict which neoantigens are most likely to bind to receptors on T cells and stimulate an immune response.
T Cell Education
The vaccine can include genetic sequences for many different neoantigens. The promise of personalized immunotherapy with mRNA vaccines is being able to activate T cells that will specifically recognize individual cancer cells based on their abnormal molecular features.
